

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-25. (canceled).

26. (currently amended) A method of inhibiting tumor growth in a mammal comprising administering to a liver cell of said mammal a compound which inhibits hydroxylation of ~~of~~ an aspartic acid or asparagine residue of an EGF-like repeat sequence of a NOTCH polypeptide, said repeat sequence comprising the amino acid sequence of SEQ ID NO:4, by an endogenous human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide, wherein said cell overexpresses said HAAH polypeptide and wherein said HAAH polypeptide comprises the amino acid sequence of SEQ ID NO:2, wherein said compound is a HAAH mutant, said mutant comprising a mutation at position 671, 679, or 690 of SEQ ID NO:2.

27. – 40 (canceled)

41. (withdrawn) The method of claim 26, wherein said tumor is a cancer of the central nervous system.

42. (originally filed) The method of claim 26, wherein said tumor is a hepatocellular carcinoma.

43. (withdrawn) The method of claim 26, wherein said tumor is a cholangiocarcinoma.

44. (withdrawn) The method of claim 26, wherein said tumor is a glioblastoma.

45. (withdrawn) The method of claim 26, wherein said tumor is a neuroblastoma.

46.- 47. (canceled)

48. (new) The method of claim 26, wherein said mutation is at position 671 of SEQ ID NO:2.

49. (new) The method of claim 26, wherein said mutation is at position 679 of SEQ ID NO:2.

50. (new) The method of claim 26, wherein said mutation is at position 690 of SEQ ID NO:2.